ClinicalTrials.gg
CompletedNCT01131182Updated Sep 21, 2022Results posted

Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)

A Phase 4 interventional study of Sitagliptin phosphate and Comparator: Sulfonylurea in Type 2 Diabetes Mellitus (T2DM), sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,147
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
9th of 197
1,147 · median 102
Started
2010
with 22 others
Phase 4
68 of 198
3 open now
Registered
90th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2010, is one of 68 in phase 4, and was the 90th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will examine whether the incidence of hypoglycemia in patients fasting for Ramadan is lower when treated with sitagliptin as compared to sulfonylurea treatment.

Read the detailed description

This study and NCT01340768 (MK-0431-262) have the same design but are conducted under separate protocols, in different countries, according to local guidelines.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Muslim men and women with type 2 diabetes
  • Participants who intend to fast during the month of Ramadan
  • Participants who have been on a stable dose of sulfonylurea for at least three months

Exclusion criteria

Exclusion Criteria:

  • Participants with type 1 diabetes mellitus
  • Pregnant or breast feeding women
  • Participants with or to dipeptidyl peptidase (DPP-4) treatment
  • Participants on insulin
  • Participants on any class of oral diabetic therapy other than sulfonylurea or metformin
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,147 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    Sitagliptin 100 mg administered orally daily as monotherapy or in combination with metformin over the Ramadan period.

    Drug: Sitagliptin phosphate · Drug: Metformin

  • Active comparator
    Sulfonylurea

    Sulfonylurea administered orally daily as monotherapy or in combination with metformin over the Ramadan period.

    Drug: Comparator: Sulfonylurea · Drug: Metformin

Interventions

  • Sitagliptin 100 mg tablet administered orally once daily over the Ramadan period.

    Also known as: Januvia

  • DrugComparator: Sulfonylurea

    Drug pages: Sulfonylurea Antidiabetic Agent · N,N''-sulfonylbis-urea

    Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription

  • Participants could continue pre-study metformin as concomitant therapy during the study.

    Also known as: Glucophage

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With at Least One Symptomatic Hypoglycemic Event

    Symptomatic hypoglycemic event was determined based on the participant's self-reported symptoms including faintness, headache, confusion, anxiety, sweating, tremor, palpitation, nausea, pallor, dizziness, hunger, and sudden behavioral change.

    Time frame: 30 days: first day of Ramadan (August 11) to last day of Ramadan (September 10)

Secondary outcomes

  1. Proportion of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event

    Hypoglycemic event was based on the participant's self-report and/or finger-stick blood glucose level. Symptomatic hypoglycemic symptoms included faintness, headache, confusion, anxiety, sweating, tremor, palpitation, nausea, pallor, dizziness, hunger, and sudden behavioral change.

    Time frame: 30 days: first day of Ramadan (August 11) to last day of Ramadan (September 10)

07

Results

Posted Jan 20, 2012

Participant flow

Participant flow — Overall Study
MilestoneSitagliptinSulfonylurea
Started529537
Completed513521
Not completed1616
Withdrew: Withdrawal by subject11
Withdrew: Lost to follow-up1415
Withdrew: Other reason10

Outcome measures

PrimaryProportion of Participants With at Least One Symptomatic Hypoglycemic Event

Symptomatic hypoglycemic event was determined based on the participant's self-reported symptoms including faintness, headache, confusion, anxiety, sweating, tremor, palpitation, nausea, pallor, dizziness, hunger, and sudden behavioral change.

Time frame:
30 days: first day of Ramadan (August 11) to last day of Ramadan (September 10)
Reported as:
Number · proportion of participants
Proportion of Participants With at Least One Symptomatic Hypoglycemic Event
proportion of participantsSitagliptinSulfonylurea
Proportion of Participants With at Least One Symptomatic Hypoglycemic Event0.070.13
Statistical analysis
  • Sitagliptin vs Sulfonylurea · Cochran-Mantel-Haenszel · p = 0.0005 (Assessed for relative risk using prior therapy (monotherapy or combination therapy) as a stratification factor.)
SecondaryProportion of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event

Hypoglycemic event was based on the participant's self-report and/or finger-stick blood glucose level. Symptomatic hypoglycemic symptoms included faintness, headache, confusion, anxiety, sweating, tremor, palpitation, nausea, pallor, dizziness, hunger, and sudden behavioral change.

Time frame:
30 days: first day of Ramadan (August 11) to last day of Ramadan (September 10)
Reported as:
Number · Proportion of participants
Proportion of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event
Proportion of participantsSitagliptinSulfonylurea
Proportion of Participants With at Least One Symptomatic or Asymptomatic Hypoglycemic Event0.080.18

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin—0/507 (0%)34/507 (6.7%)
Sulfonylurea—3/514 (0.6%)68/514 (13.2%)
Most frequent serious events
Most frequent serious events
EventSitagliptinSulfonylurea
Pancreatitis acuteGastrointestinal disorders0/5071/514
Urinary Tract InfectionInfections and infestations0/5071/514
Ischaemic strokeNervous system disorders0/5071/514
Most frequent other events
Most frequent other events
EventSitagliptinSulfonylurea
HeadacheNervous system disorders25/50744/514
DizzinessNervous system disorders20/50738/514
HungerGeneral disorders13/50735/514
TremorNervous system disorders7/50734/514
HyperhidrosisSkin and subcutaneous tissue disorders19/50732/514

Baseline characteristics

Age, Continuous
Age, Continuous(years)SitagliptinSulfonylureaTotal
Mean55 ± 1155 ± 1055 ± 11
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinSulfonylureaTotal
Female238259497
Male269255524
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Al Sifri S, Basiounny A, Echtay A, Al Omari M, Harman-Boehm I, Kaddaha G, Al Tayeb K, Mahfouz AS, Al Elq A, Radican L, Ozesen C, Katzeff HL, Musser BJ, Suryawanshi S, Girman CJ, Davies MJ, Engel SS; 2010 Ramadan Study Group. The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial. Int J Clin Pract. 2011 Nov;65(11):1132-40. doi: 10.1111/j.1742-1241.2011.02797.x. Epub 2011 Sep 27. PubMed 21951832 ↗

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2010 to primary completion in Nov 2010, 4 months.

Results were first posted in Jan 2012, 1 year 2 months after primary completion. A results delay was requested in Nov 2011.

Of 132 industry-sponsored phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 4 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2010
First posted
May 26, 2010
StartActual
Jun 13, 2010
Primary completionActual
Nov 4, 2010
CompletionActual
Nov 4, 2010
Results delay requested
Nov 2, 2011
Results first posted
Jan 20, 2012
Last update
Sep 21, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01131182
Responsible party
Sponsor
First posted
May 26, 2010
Start date
Jun 13, 2010
Primary completion
Nov 4, 2010
Completion
Nov 4, 2010
Results posted
Jan 20, 2012
Last update
Sep 21, 2022

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion